VivoSim Labs (VIVS) Current Deferred Revenue (2011 - 2019)
VivoSim Labs (VIVS) posted quarterly Current Deferred Revenue of $532000.0 for Q2 2019, down 15.29% year-over-year from $628000.0 in Q2 2018, and up 1420.0% quarter-over-quarter from $35000.0 in Q1 2019.
VivoSim Labs (VIVS) Current Deferred Revenue (2011 - 2019) Analysis & Trends
VivoSim Labs' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $532000.0 for Q2 2019.
- In Q2 2019, Current Deferred Revenue fell 15.29% year-over-year to $532000.0; the TTM figure through Jun 2019 stood at $532000.0 (down 15.29% YoY), while the FY2019 annual figure was $35000.0, down 94.76% from the prior year.
- Current Deferred Revenue for Q2 2019 stood at $532000.0, up from $35000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.4 million in Q4 2015, with the low at $35000.0 in Q1 2019.
- The 5-year median for Current Deferred Revenue is $600500.0 (2017), against an average of $619500.0.
- The sharpest annual moves came in 2015 and 2019: Current Deferred Revenue surged 5738.46% in 2015, then plunged 94.76% in 2019.
- VivoSim Labs' Current Deferred Revenue stood at $1.4 million in 2015, then tumbled by 89.27% to $155000.0 in 2016, then climbed by 16.13% to $180000.0 in 2017, then surged by 222.22% to $580000.0 in 2018, then fell by 8.28% to $532000.0 in 2019.
- Business Quant data shows VIVS's Current Deferred Revenue at $532000.0 in Q2 2019, $35000.0 in Q1 2019, and $580000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 532,000.00 |
| Mar 31, 2019 | 35,000.00 |
| Dec 31, 2018 | 580,000.00 |
| Sep 30, 2018 | 619,000.00 |
| Jun 30, 2018 | 628,000.00 |
| Mar 31, 2018 | 668,000.00 |
| Dec 31, 2017 | 180,000.00 |
| Sep 30, 2017 | 173,000.00 |
| Jun 30, 2017 | 854,000.00 |
| Mar 31, 2017 | 582,000.00 |
| Dec 31, 2016 | 155,000.00 |
| Sep 30, 2016 | 147,000.00 |
| Jun 30, 2016 | 140,000.00 |
| Mar 31, 2016 | 1.11 Mn |
| Dec 31, 2015 | 1.44 Mn |
| Sep 30, 2015 | 1.11 Mn |
| Jun 30, 2015 | 1.43 Mn |
| Mar 31, 2015 | 759,000.00 |
| Dec 31, 2014 | 241,000.00 |
| Sep 30, 2014 | 140,000.00 |